surpass cvot tirzepatide Efficacy and safety of in children and adolescents with type 2 diabetes (SURPASS-PEDS): a randomised, double-blind, placebo-controlled, phase 3 trial Tirzepatide and Cardiovascular Outcomes: A

Use the dosage calculator tools at SeekPeptides to determine exactly how many units correspond to your target dose

Retatrutide does not yet have a published head-to-head trial comparing it to the other two drugs

Lilly has been offering the vials only to patients paying on their own without insurance, also known as self-pay

What other potential therapeutic areas could GLP-1s address, where is the white space, and how should companies evaluate where to play

There are specific circumstances in which you should seek prompt medical advice, either from your trial team or your GP: Persistent insomnia lasting more than three to four weeks that is significantly affecting your daytime functioning, mood, or concentration Symptoms of anxiety or low mood that have developed or worsened since starting treatment, as these can both cause and be exacerbated by poor sleep Signs of obstructive sleep apnoea such as loud snoring, gasping during sleep (reported by a partner), or excessive daytime sleepiness which require formal assessment and may need referral to a sleep clinic New or worsening palpitations or an irregular heartbeat at night GLP-1-based medicines can be associated with a modest increase in resting heart rate